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Abstract. In primary malignant liver tumors, trypsinogen-
immunoreactivity was present in 70% of intrahepatic
cholangiocarcinoma (ICC) specimens, but absent in hepato-
cellular carcinoma (HCC) specimens. We suggest the
secretion of trypsinogen to be a key difference in biological
behavior between ICC and HCC cells. The purpose of this
study was to investigate the secretion of tumor-derived trypsin
and the expression of its specific receptor, protease-activated
receptor-2 (PAR-2), in ICC using cell lines and surgical
specimens. The expression of trypsinogen-1 mRNA was
observed in three of four ICC cell lines, but none of three
HCC cell lines. Western blot analysis detected trypsinogen-1
in serum-free conditioned medium from one of the ICC cell
lines positive for the mRNA. Gelatin zymography revealed a
gelatinolytic activity for trypsin, the activated form of trypsi-
nogen, in the same conditioned medium. PAR-2 mRNA and
protein were observed in ICC cell lines. The proliferative
activity of ICC cells was increased by concentrations of trypsin
as low as 10 nM, and peaked at 100 nM. The effect of trypsin
was suppressed by a serine protease inhibitor, gabexate
mesilate. PAR-2 expression was detected in 64% of ICC
surgical specimens immunohistochemically. In addition,
stroma fibroblasts expressed PAR-2 in 52% of ICC specimens.
These results suggest that trypsinogen-1 contributes to the
growth of ICC cells and also tumor-associated fibroblasts.
Introduction
Both intrahepatic cholangiocarcinoma (ICC) and hepato-
cellular carcinoma (HCC) are primary malignant liver tumors.
ICC is relatively rare, despite being the second most common
primary hepatic malignancy after HCC. It reportedly comprises
only 5-10% of primary liver neoplasms (1). Even though both
these tumor types spread into hepatic parenchyma, they differ
in biological behavior. Clinically, ICC frequently recurs
despite surgical curative resection (2,3) and adjuvant chemo-
therapy (4), and has a poor prognosis compared with HCC
(5). Histologically, ICC is an adenocarcinoma showing
tubular or papillary structures with a variable fibrous
stroma (6,7) (Fig. 1A), while HCC consists of tumor cells
that resemble hepatocytes (7) (Fig. 1B). The scirrhous type
characterized by marked fibrosis is uncommon in HCC (7).
We predict that there is an essential difference in growth and
progression between ICC and HCC correlated with each
cancer cellular characteristics.
Trypsinogen is a digestive enzyme produced by pancreatic
acinal cells, and is one of the serine proteases. Trypsin, the
activated form of trypsinogen, has the characteristics of
activating matrix metalloproteases and also possesses
gelatinolytic activity (8). Previous studies have shown that a
variety of cancer cell lines and cancer tissues express this
enzyme (9-13). Koshikawa et al identified 1- and 2-chain
forms of trypsinogen-1 (cationic trypsinogen) in a gastric
carcinoma cell line (14). Under acidic conditions that prevail
in the extracelluar space between malignant tumor cells,
trypsinogen-1 is spontaneously converted to trypsin (15).
We previously reported that when a pancreatic cancer cell
line that lacked expression of trypsinogen mRNA was
transfected with trypsinogen-1 cDNA, the cells secreted
trypsinogen and acquired significantly greater invasive ability
(16). In addition, we demonstrated in pancreatic cancer
cell lines that hepatic metastasis and invasive ability were
correlated with the amount of trypsinogen-1 and were
inhibited by a serine protease inhibitor (17). Thus, trypsin
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plays an essential role in facilitating the invasion and metas-
tasis of the cancer cells.
Previous studies have described protease-activated
receptor-2 (PAR-2) as one of the G protein-coupled receptors
that is activated by trypsin (18-20). PAR-2 activation induces
a number of physiologic processes, and its agonist, trypsin is
considered a signaling molecule (21). PAR-2 expression has
been found in certain human solid tumors, such as gastric,
colon and pancreatic cancer (22-26). Furthermore, several
studies have suggested that trypsin plays a pivotal role in pro-
liferation and serves as a potent mitogen in PAR2-positive
cancer cells (22-26). The proliferative effect of the PAR-2
signal is mediated by the MEK-MAP kinase cascade (23,27).
With regard to ICC and HCC, 70% of ICC specimens
expressed trypsinogen but the immunoreactivity was absent
in HCC specimens (28). Therefore, we suggest that the
relationship between trypsinogen secreted by the cancer cells
and its specific receptor, PAR-2, might contribute to the
proliferation of ICC cells, revealing a difference in biological
behavior between ICC and HCC. Thus, in this study, we
examined whether ICC cells secrete trypsinogen-1 and express
PAR-2 protein using tissue specimens and cell lines. We also
investigated whether the proliferation of ICC cells expressing
PAR-2 was enhanced by trypsin.
Materials and methods
ICC and HCC specimens. ICC specimens: between December
1998 and October 2008, 25 patients with ICC underwent
surgical resection at the Kanazawa University Hospital. ICC
was defined as an intrahepatic cholangiocarcinoma without
any detectable extrahepatic primary tumor. Of the 25 patients,
14 were men and 11 were women, with a mean age of 64.3
(range: 35-84) years. The gross appearance of the cut surface
of ICC was categorized into the following types according to
the Liver Cancer Study Group of Japan classification system
for Primary Liver Cancer (29): mass forming (MF), periductal
infiltrating (PI), intraductal growth (IG) and other. Of the 25
patients, 16 (64%) had the MF type of ICC, six (24%) had
the MF + PI type, two (8%) had the PI type and one (4%) had
the IG type. HCC specimens: between September 2001 and
August 2006, 148 patients with HCC underwent surgical
resection at the Kanazawa University Hospital. We selected
15 of the 148 patients at random: 11 men and 4 women, with
a mean age of 65.7 (range: 52-77) years.
Cell lines and culture conditions. Four ICC cell lines
(HuCCT-1, IHGGK and HuH28 from the Cell Resource
Center for Biochemical Research, Tohoku University, Sendai,
Japan; and CCKS-1 from the Department of Human Pathology,
Kanazawa University, Kanazawa, Japan) and three HCC cell
lines (HuH7 from the Cell Resource Center for Biochemical
Research; HepG2 from the Bioresource Center, Tsukuba,
Japan; and HLE from the Health Science Research Resources
Bank, JCRB Cellbank, Tokyo, Japan) were used. CCKS-1,
HuCCT-1, IHGGK and HuH28 cells were maintained in
RPMI-1640 medium (Nissui Pharmaceutical, Tokyo, Japan),
whereas HepG2, HLE and HuH7 cells were maintained in
Dulbecco's modified Eagle's medium (Invitrogen Corporation,
Tokyo, Japan) supplemented with 2 mM glutamine (Nissui
Pharmaceutical), 10% fetal bovine serum (FBS) (Nichirei
Biosciences Inc., Tokyo, Japan), 100 U/l penicillin and 100 μg/
ml streptomycin (Invitrogen Corporation, Tokyo, Japan) at
37˚C in a 5% COs incubator. 
Antibodies. As primary antibodies, we used a mouse anti-
trypsin monoclonal antibody (Nihon Millipore K.K., Tokyo,
Japan), and a mouse anti-PAR-2 monoclonal antibody (Santa
Cruz, CA, USA).
Chemicals. Active trypsin (trypsin from bovine pancreas,
sequencing grade for biochemistry) was obtained from Wako
Pure Chemical Industries (Tokyo, Japan).
Immunohistochemistry. Immunostaining of surgically resected
ICC and HCC tissues was performed on 10% formalin-fixed,
paraffin-embedded samples using a streptavidin-biotin-
peroxidase method. Briefly, 4 μm-thick sections were
mounted on poly-L-lysine-coated glass slides, air-dried, and
deparaffinized with graded xylene and alcohol solutions.
After treatment by microwave, endogenous peroxidase
activity was suppressed with 0.3% hydrogen peroxide and
methanol. The sections were treated with 5% hydrogen
normal goat serum to block non-specific binding. They were
incubated with the mouse anti-trypsin monoclonal antibody
(1:300) or mouse anti-PAR-2 monoclonal antibody (1:100)
overnight at 4˚C. The sections were rinsed in PBS and
incubated with biotinylated anti-mouse IgG (Dako Envision
System, Dako Japan, Kyoto, Japan) for 60 min followed by
peroxidase-labeled streptavidin (Dako Envision System) for
5 min at room temperature. Reaction products were developed
in a 0.02% 3,3'-diaminobenzidine tetrahydrochloride solution
containing 0.1% H2O2 (Dako Envision System). The cells
were counterstained with hematoxylin.
Immunocytochemistry. For the localization of PAR-2 in ICC
cells, each cancer cell line was grown on Lab-Tec chamber
slides (Nalge Nunc International, New York, NY), and then
fixed in a mixture of methanol and acetone (1:1) for 15 min.
Immunostaining was performed as reported (24,30). Briefly,
the slides were immersed in methanol containing 0.3% H2O2
for 30 min, blocked with 3.3% normal goat serum in PBS,
and incubated with the mouse anti-PAR-2 monoclonal
antibody (1:80) at 4˚C overnight. After the sections were
washed in PBS, the immunoreactivity was visualized by
incubating the sections with anti-mouse IgG antibody con-
jugated with Alexa Fluor488 (Molecular Probes, Eugene,
OR) (1:400) for 1 h at room temperature. The sections were
counterstained in the nucleus with 100 ng/ml of bisbenzimide
H33258 (Hoechst 33258) (Sigma-Aldrich, St. Louis, MO).
They were then observed with an immunofluoresence micro-
scope (BX50/BX-FLA, Olympus, Tokyo, Japan).
Reverse transcription-polymerase chain reaction (RT-PCR).
Total RNA was isolated from each cancer cell line and normal
pancreas tissue from surgical specimens by the acid guani-
dinium thiocyanate-phenol-chloroform method (31). RT-PCR
was performed as described (24). The following primers were
purchased from Takara Bio Inc. (Shiga, Japan): for human
trypsinogen-1 (32), forward 5'-ACCACCATGAATCCACC
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ACTCCTG-3' and reverse 5'-GCTTTAGCTATTGGCA
GCTAT-3'; for PAR-2, forward 5'-CTGACCTCCTCTC
TGTCATC-3' and reverse 5'-GGACAGTGACAATGA
GTTTG-3'; and for glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), forward 5'-ACCACAGTCCATGCCA
TCAC-3' and reverse 5'-TCCACCACCCTGTTGCTGTA-3'.
Amplification of GAPDH was used as a control for sample
loading and integrity. The conditions for using Ex Tag
polymerase (Takara Bio Inc.) were: denaturation at 94˚C for
30 sec, annealing at 54˚C for 1 min, and extension at 72˚C for
1 min a total of 38 times for trypsinogen-1, and 35 times for
PAR-2 and GAPDH.
Gelatin zymography. The preparation and concentration of
serum-free conditioned media were performed as reported
(14). Briefly, cells were grown to semiconfluence in 100 mm
dishes containing 10 ml of RPMI-1640 medium supplemented
with 10% FBS. The culture was washed twice with PBS and
then replaced with serum-free RPMI-1640 medium. After 5
days, the culture medium was titrated with 1N HCl to pH 5.5
or 6.5, because trypsinogen-1 is spontaneously converted to
trypsin under acidic conditions (8,15). Then the medium was
incubated at 37˚C for 3 h. The resulting supernatant was con-
centrated 50 times using Vivaspin 4 (Sartorius Stedim Biotech
GmbH, Goettingen, Germany). The conditioned medium was
processed for gelatin zymography as described previously
(10,33). Gelatinolytic bands were visualized by staining with
Coomassie Brilliant Blue R-250 after incubation in 50 mM
Tris-HCl (pH 7.5) containing 5 mM CaCl2 at 37˚C for 20 h.
Western blot analysis. Western blotting was performed as
described (24). The same conditioned medium was used as in
gelatin zymography. The protein concentration of each
sample was measured using a BCA protein assay kit (Thermo
Scientific, Yokohama, Japan). For SDS-PAGE, 20 μg of
protein from each sample was loaded on a 5-20% gradient
polyacrylamide gel (e-PAGEL, Atto Corporation, Tokyo,
Japan). Proteins were transferred to PVDF membranes (Bio-
Rad Laboratories, Hercules, CA), then blocked with
commercial gradient buffer (EzBlock, Atto Corporation) at
room temperature for 30 min. The membrane was incubated
with the mouse anti-trypsin antibody (1:1000) or mouse anti-
PAR-2 antibody (1:100) as the primary antibody at room
temperature for 1 h. After being washed with commercial
gradient buffer (EzWash, Atto Corporation), the membrane
was incubated with a horseradish peroxidase-conjugated anti-
mouse IgG antibody (ECL Plus Western blotting reagent
reagent pack (Amersham, Little Chalfont, UK) for 1 h at
room temperature. Detection of chemiluminescence was
performed with the ECL Plus Western blotting reagent
detection system (Amersham).
Cell growth assay. The proliferative effect of active trypsin
on ICC cell lines was quantified using the MTS assay
according to the manufacturer's instructions. CCKS-1 cells
(0.5x104/well) were grown in 96-well plates in medium with
10% FBS for 48 h. The medium was then removed and the
cells were subsequently incubated in serum-free medium
containing different concentrations (0.1 to 100 nM) of active
trypsin or 10% FBS for 72 h. Briefly, at the end of the period
of exposure to trypsin, 20 μl of the MTS reagent (CellTiter
96 aqueous solution, Promega, Madison, WI) was added to
100 μl of medium in each well. Cells were further cultured
for 3 h and the resultant absorbance was recorded at 490 nm
using a 96-well plate reader (EAR 340 AT, SLT, Vienna,
Austria).
In some experiments, the proliferation assay was carried
out in the presence of both 100 nM active trypsin and different
concentrations of a serine protease inhibitor, gabexate mesilate
(FOY-007, Ono Pharmaceutical Co., Osaka, Japan). Cancer
cells were seeded on 96-well plates in medium with 10% FBS
for 48 h. The cells were exposed to 100 nM active trypsin
and a concentration of gabexate mesilate (0.01 to 1 mM) for
3 days. The number of cells was counted using the MTS
assay.
Data represent the mean ± SD from three different
experiments and are expressed as a percentage of the number
of cells in untreated controls.
Statistical analysis. Statistical analyses were carried out using
Student's unpaired t-test. p<0.05 was considered statistically
significant.
Results
Detection of tumor-derived trypsinogen/trysin in ICC and
HCC tissues. In 13 of the 25 ICC surgical specimens (54%),
INTERNATIONAL JOURNAL OF ONCOLOGY  36:  793-800,  2010
Figure 1. Histological finding of H&E for ICC (A) and HCC (B). (A) ICC is
an adenocarcinoma showing tubular or papillary structures with a variable
fibrous stroma. (B) HCC consists of tumor cells that resemble hepatocytes.
A
B
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trypsin was detected in >10% of carcinoma cells by immuno-
histochemistry (Fig. 2A). Trypsin-immunoreactivity was
evident throughout the cytoplasm of ICC cells. In addition,
trypsin was weakly expressed in the ICC cancer stroma.
However, trypsin was not detected in HCC tissues (Fig. 2B).
These results are consistent with those of our previous study
(28).
Expression of tripsinogen-1 mRNA in ICC and HCC cell
lines. A RT-PCR analysis of trypsinogen-1 was conducted
with the ICC and HCC cell lines. Normal pancreas tissue was
used as a positive control. Trypsinogen-1 expression at the
mRNA level was observed in three of the four ICC cell lines,
HUCCT-1, CCKS-1, and HuH28, but none of the three HCC
cell lines (Fig. 3). These results confirm that trypsinogen-1
mRNA was expressed specifically in ICC cell lines.
The secretion of tumor-derived trypsinogen/trypsin in the
supernatant of cultured ICC cells. To examine whether
trypsinogen-1 was secreted extracellularly and convertible to
the active form trypsin, we performed Western blotting and
gelatin zymography with serum-free conditioned medium
prepared from an ICC cell line, CCKS-1, positive for
trypsinogen-1 mRNA. The Western blot analysis revealed
two bands at 23 and 25 kDa (Fig. 4). These bands were well
consistent with those reported for the activated forms of 2- and
1-chain trypsinogen-1, respectively (14). Gelatin zymography
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Figure 2. Immunohistochemical staining for trypsin in ICC (A) and HCC
(B) tissues. (A) Trypsin was evident in ICC cancer cells which showed
tubular structures. (B) HCC tissues. There was no staining in HCC cells. 
Figure 3. RT-PCR analysis of ICC and HCC cell lines for trypsinogen-1.
Three ICC cell lines, CCKS-1, HuCCT-1 and HuH28, expressed
trypsinogen-1. One of the ICC cell lines, IHGGK, and the three HCC cell
lines, HepG2, HLE and HuH-7, did not express this enzyme. Normal human
pancreas was used as a positive control. Amplification of GAPDH gene
expression was used as a control for sample loading and integrity.
Figure 4. Western blot analysis for trypsin secreted into the medium from
CCKS-1 cells (positive for trypsinogen-1 mRNA). The medium showed two
bands (23 and 25 kDa) well consistent with the activated forms of 2- and 1-
chain trypsinogen-1.
Figure 5. Zymographic analysis for proteolytic enzymes secreted into the
medium from CCKS-1 cells (positive for trypsinogen-1 mRNA).
Gelatinolytic activity at a molecular weight of ~23 kDa corresponding to
trypsin appeared in the conditioned medium of CCKS-1 cells. Additional
gelatinolytic activity, consistent with MMP-2 (72 kDa) and MMP-9 (92 kDa),
was present in the same medium.
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showed a gelatinolytic band with a molecular weight of
~23-25 kDa corresponding to trypsin (Fig. 5). This band was
consistent with that reported for the activated form of
trypsinogen-1 (14,16). In addition, the supernatant exhibited
gelatinolytic activity with bands at ~72 and 92 kDa. Similar
bands were reported previously: the first protease corresponding
to MMP-2, the second, to MMP-9 (34). There was no
difference in the results whether the medium was titrated to
pH 5.5 or 6.5 (data not shown).
Detection of PAR-2 expression in ICC tissues. In 17 of the
25 ICC surgical specimens (68%), PAR-2 was detected in
>10% of carcinoma cells by immunohistochemistry (Fig. 6).
PAR-2-immunoreactivity was evident throughout the cyto-
plasm of ICC cells. In addition, the cancer stroma showed
expression of PAR-2 in 13 of the 25 ICC specimens (52%)
(Fig. 6).
Expression of PAR-2 mRNA and protein in ICC cell lines.
We examined the expression of PAR-2 mRNA in ICC cell
lines using RT-PCR. The mRNA was observed in three
of four ICC cell lines, HUCCT-1, CCKS-1, and IHGGK
(Fig. 7). To quantify the expression of PAR-2 protein, we
performed Western blot analysis using a specific mono-
clonal antibody against human PAR-2. Two ICC cell lines,
CCKS-1 and HuCCT-1 which expressed PAR-2 mRNA,
showed a band of ~55 kDa corresponding to the known
molecular weight of PAR-2 (Fig. 8).
Expression and cellular localization of PAR-2 protein in ICC
cell lines. To confirm the cellular localization of PAR-2 in
ICC cell lines, we performed immunofluorescence micro-
scopy using the mouse anti-PAR-2 antibody and negative
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Figure 6. Immunohistochemical staining for PAR-2 in ICC tissues. ICC
cells (arrowheads) and stromal fibroblasts (arrows) expressed PAR-2. The
immunostaining of PAR-2 was diffuse in the cytoplasma of ICC cells. ICC
stromal fibroblasts were also homogeneously positive for PAR-2.
Figure 7. RT-PCR analysis of ICC cell lines for PAR-2. Three ICC cell
lines, CCKS-1, HuCCT-1 and IHGGK, expressed PAR-2. One of the ICC
cell lines, HuH28, did not express PAR-2. Amplification of the GAPDH
gene was used as a control for sample loading and integrity.
Figure 8. Western blot analysis of ICC cell lines (positive for PAR-2
mRNA) for PAR-2. Two ICC cell lines, CCKS-1 and HuCCT-1, showed a
band of ~55 kDa corresponding to the known molecular weight of PAR-2.
A
B
Figure 9. Fluorescence immunocytochemistry for PAR-2 in ICC cell lines.
CCKS-1 (A) and HuCCT-1 (B) were incubated with anti-PAR-2 mono-
clonal antibody. PAR-2-immunoreactivity (green) was present predominantly
in the cytoplasm in both cell lines.
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control antibodies. Cancer cells were detected by the
presence of blue nuclei, PAR-2-immunoreactivity was
green. PAR-2 was intense in both CCKS-1 (Fig. 9A) and
HuCCT-1 (Fig. 9B) cells and was observed in the entire
cytoplasm. These results were consistent with the level of
PAR-2 expression determined by Western blotting.
Effect of trypsin on the growth of ICC cell lines. To examine
the effect of the PAR-2 activator, trypsin, on the growth of
ICC cells, CCKS-1 was treated with either active trypsin
(0.1 to 100 nM) or 10% FBS, and proliferative activity was
quantified by the MTS assay. In CCKS-1 cells which showed
immunoreactivity to PAR-2, 3 days of treatment with active
trypsin induced a significant increase in cell number (Fig. 10).
The MTS assay showed a dose-dependent increase in pro-
liferative activity, and the effect induced by 100 nM active
trypsin was almost 35% of that induced by 10% FBS. At higher
concentrations (≥1 μM), the cancer cells detached from the
plastic culture dishes, and the proliferation assay was no longer
reliable.
In addition, we determined whether trypsin-induced pro-
liferation in ICC cells was inhibited by gabexate mesilate, a
potent inhibitor of serine protease. CCKS-1 cells were cultured
with various concentrations of gabexate mesilate for 3 days,
and cell numbers were counted by the MTS assay. Gabexate
mesilate completely inhibited the 100 nM trypsin-induced
proliferative response at a concentration of 0.1 mM (Fig. 11).
Recent studies found that gabexate mesilate at 0.01 mM and
0.1 mM did not have a significant effect on the proliferation
of colon and pancreatic cancer cell lines, whereas at a con-
centration of 1 mM, the number of cells was markedly reduced
after 3 days of culture (35,36). Therefore, we suggested that
gabexate mesilate (0.01 and 0.1 mM) had no cytotoxic effect.
These results demonstrate that the suppressive effect of
gabexate mesilate on cell growth resulted from inhibition of
trypsin, not from non-specific cytotoxicity.
Discussion
Active trypsin, produced and secreted by cancer cells, plays
an essential role in facilitating invasion and metastasis by
digesting components of the extracellular matrix (8-14,16,17).
At the same time, the contribution of PAR-2 and the effect of
active trypsin on signaling pathways influencing malignant
tumors are still being studied (22-27). With regard to tumor-
derived trypsin in primary malignant liver tumors, our previous
study demonstrated trypsinogen immunoreactivity in ICC
tissues but not in HCC tissues (28), and Lempinen et al
(37) suggested that serum trypsinogen-2 was a useful marker
for diagnosing patients with cholangiocarcinoma, superior
to serum CA19-9 and CEA. However, the secretion of
trypsinogen in primary malignant liver tumors is still unknown.
Furthermore, PAR-2 expression in primary malignant liver
tumors has not been examined.
In the present study, we showed that trypsinogen-1 was
secreted in serum-free conditioned medium of an ICC cell
line by Western blotting and detected active trypsin by gelatin
zymography in the same medium. On the other hand, by RT-
PCR, the expression of trypsinogen-1 was not detectable in
HCC cell lines. In addition, PAR-2 was detected in ICC cell
lines by RT-PCR and Western blotting. Also, ICC cell lines
showed PAR-2-immunoreactivity throughout the cytoplasm.
We further demonstrated that trypsin at a concentration as low
as 10 nM enhanced proliferative activity in ICC cells. The
activity peaked at a concentration of 100 nM. These results
are consistent with those in our previous study on PAR-2-
positive pancreatic cancer cell lines (24). The enhanced proli-
feration was suppressed by gabexate mesilate, a potent
inhibitor of serine protease. Given that trypsin induced the
proliferation of PAR-2-positive human pancreatic, colon,
gastric, breast and cervical cancers in vitro (22-27), we suggest
that trypsin secreted by ICC cells has the same effect on
PAR-2-positive ICC cells in an autocrine manner. This study
is the first indication of the enhancement of proliferative
NAKANUMA et al:  THE EXPRESSION OF TRYPSIN AND PAR-2 IN INTRAHEPATIC CHOLANGIOCARCINOMA
Figure 10. ICC cancer cells were treated with different concentrations
(0.1-100 nM) of PAR-2 activator, trypsin or 10% FBS, and the prolife-
rative effect was quantified by the MTS assay. Trypsin induced a dose-
dependent increase in proliferative activity. The graph shows representative
data for CCKS-1 cells. Results are the mean ± SD for three different
experiments.
Figure 11. Effect of gabexate mesilate, a potent inhibitor of serine protease,
on the trypsin-induced proliferative response. Gabexate mesilate completely
inhibited the 100 nM trypsin-induced proliferative response at a concentration
of 0.1 mM in CCKS-1. Results are the mean ± SD for three different
experiments.
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activity by trypsin in PAR-2-positive ICC cells. These results
show the secretion of trypsinogen to represent a novel
difference in biological behavior between ICC and HCC.
ICC shows a variable fibrous stroma, but 74.2% of ICCs
occur in normal liver (5). On the other hand, fibrotic change
is uncommon in HCC, but 80.3% of HCCs arise from fibrotic
liver (5). Based on these results, the degree of fibrosis in the
primary liver tumor may not correlate well with the degree of
fibrosis in the background hepatic parenchyma. We suggest
that there is a fibrotic mechanism independent of the back-
ground hepatic parenchyma in primary liver tumor, especially
in ICC. The stroma has been thought to passively support
tumor development and progression, and there is increasing
evidence that the stroma activity contributes to the growth
and invasion of malignant tumors (38,39).
In our study, PAR-2-immunoreactivity was observed in
52% of ICC stromas including tumor-associated fibroblasts.
The involvement of PAR-2 in the cancer stroma has recently
begun to be elucidated. Two previous studies demonstrated
that stromal fibroblasts expressed PAR-2 in pancreatic cancer
and breast cancer (40,41). Interestingly, researchers have also
reported that PAR-2 is a potential factor in the pathogenesis
of several inflammatory diseases, fibrotic disease in clinical
studies (42,43) and experimental studies (44,45). Our results
suggest that in the ICC microenvironment, exposure to trypsin
induced the proliferation of fibroblasts on PAR-2 stimulation,
while in the  non-exposed HCC microenvironment it did not.
Trypsin may have not only an autocrine effect on PAR-2-
positive cancer cells but also a paracrine effect on PAR-2-
positive tumor-associated fibroblasts. Although the mechanism
of fibrosis in ICC is still poorly understood, its worth
investigating the influence of trypsin and PAR-2 on tumor-
associated fibroblasts.
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